CEO Kevin Lobo is optimistic about the company's growth trajectory, aiming for 10% organic growth in Q4. CFO Glenn Boehnlein highlights cost-saving initiatives driving margin expansion. Strong international hip sales are fueled by product innovation, with positive early feedback on Mako Spine.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing